EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.

Fiche publication

Date publication

février 2026

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Lin SH, Kahangire DA, Nagar SP, Ahn MJ, Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy RR

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41825181

Résumé

Historically, resection followed by chemotherapy was standard treatment for stage II-III non-small cell lung cancer (NSCLC) and selected patients with stage IB disease. However, recurrence was common post-resection. Genomic characterization of early-stage NSCLC and precision medicine have since provided more effective therapies. Real-world evidence prior to practice-changing approvals aids understanding of the disease and treatment landscape, and establishment of benchmarks for future studies. We report an international, retrospective, real-world study of patients with early-stage NSCLC.